Cyclacel Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: BGMSP · Form: 10-Q · Filed: May 14, 2024 · CIK: 1130166
Sentiment: neutral
Topics: 10-Q, Financials, Equity, Stock Options, Securities Purchase Agreement
TL;DR
<b>Cyclacel Pharmaceuticals, Inc. filed its Q1 2024 10-Q, detailing financial positions and equity-related information.</b>
AI Summary
Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Cyclacel Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to preferred stock, common stock, and retained earnings as of March 31, 2024, and comparative periods. Information on employee stock options and restricted stock units (RSUs) is provided for various periods. The company references its Equity Incentive Plan 2018 and Inducement Equity Incentive Plan 2020. Subsequent events, including an April 2024 Securities Purchase Agreement, are noted.
Why It Matters
For investors and stakeholders tracking Cyclacel Pharmaceuticals, Inc., this filing contains several important signals. The 10-Q filing provides a snapshot of the company's financial health and equity structure as of the end of the first quarter of 2024. Details on stock options, RSUs, and incentive plans are crucial for understanding executive compensation and potential future dilution.
Risk Assessment
Risk Level: medium — Cyclacel Pharmaceuticals, Inc. shows moderate risk based on this filing. The company's financial performance and future prospects are not detailed in this filing, which primarily focuses on balance sheet items and equity structures, making it difficult to assess its current operational health or growth trajectory.
Analyst Insight
Review the full 10-Q to understand the specific financial details, including any revenue or net income figures, and the implications of the April 2024 Securities Purchase Agreement.
Key Numbers
- 2024-03-31 — Reporting Period End Date (Conformed period of report)
- 2024-05-14 — Filing Date (Filed as of date)
- 2023-12-31 — Previous Fiscal Year End (Fiscal year end)
- 2021-08-12 — Cantor Fitzgerald Co. Member Date (cycc:CantorFitzgeraldCo.Member)
- 2023-12-21 — December 2023 Insider Private Placement Date (cycc:December2023InsiderPrivatePlacementMember)
- 2020-10-31 — Inducement Equity Incentive Plan 2020 Date (cycc:InducementEquityIncentivePlan2020Member)
- 2024-04-30 — April 2024 Securities Purchase Agreement Date (us-gaap:SubsequentEventMember cycc:April2024SecuritiesPurchaseAgreementMember)
- 2024-05-01 — Subsequent Event Period Start Date (us-gaap:SubsequentEventMember)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Filer name
- 2024-03-31 (date) — Conformed period of report
- 2024-05-14 (date) — Filed as of date
- 2834 (sic_code) — Standard Industrial Classification
- 908-517-7330 (phone) — Business phone
- XCYTE THERAPIES INC (company) — Former company name
- 2000-12-18 (date) — Date of name change
- 2024-04-30 (date) — April 2024 Securities Purchase Agreement date
FAQ
When did Cyclacel Pharmaceuticals, Inc. file this 10-Q?
Cyclacel Pharmaceuticals, Inc. filed this Quarterly Report (10-Q) with the SEC on May 14, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by Cyclacel Pharmaceuticals, Inc. (BGMSP).
Where can I read the original 10-Q filing from Cyclacel Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cyclacel Pharmaceuticals, Inc..
What are the key takeaways from Cyclacel Pharmaceuticals, Inc.'s 10-Q?
Cyclacel Pharmaceuticals, Inc. filed this 10-Q on May 14, 2024. Key takeaways: Cyclacel Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024.. The filing includes data related to preferred stock, common stock, and retained earnings as of March 31, 2024, and comparative periods.. Information on employee stock options and restricted stock units (RSUs) is provided for various periods..
Is Cyclacel Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this 10-Q, Cyclacel Pharmaceuticals, Inc. presents a moderate-risk profile. The company's financial performance and future prospects are not detailed in this filing, which primarily focuses on balance sheet items and equity structures, making it difficult to assess its current operational health or growth trajectory.
What should investors do after reading Cyclacel Pharmaceuticals, Inc.'s 10-Q?
Review the full 10-Q to understand the specific financial details, including any revenue or net income figures, and the implications of the April 2024 Securities Purchase Agreement. The overall sentiment from this filing is neutral.
Key Dates
- 2024-03-31: Quarterly Period End — Financial reporting period for the 10-Q
Filing Stats: 4,552 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-05-14 17:12:45
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Mar
- $000 — INC. CONSOLIDATED BALANCE SHEETS (In $000s, except share, per share, and liquidat
Filing Documents
- cycc-20240331x10q.htm (10-Q) — 1017KB
- cycc-20240331xex31d1.htm (EX-31.1) — 14KB
- cycc-20240331xex31d2.htm (EX-31.2) — 15KB
- cycc-20240331xex32d1.htm (EX-32.1) — 5KB
- cycc-20240331xex32d2.htm (EX-32.2) — 5KB
- cycc-20240331x10q001.jpg (GRAPHIC) — 19KB
- cycc-20240331x10q002.jpg (GRAPHIC) — 32KB
- 0001558370-24-008159.txt ( ) — 5018KB
- cycc-20240331.xsd (EX-101.SCH) — 41KB
- cycc-20240331_cal.xml (EX-101.CAL) — 34KB
- cycc-20240331_def.xml (EX-101.DEF) — 202KB
- cycc-20240331_lab.xml (EX-101.LAB) — 331KB
- cycc-20240331_pre.xml (EX-101.PRE) — 277KB
- cycc-20240331x10q_htm.xml (XML) — 650KB
Financial Information
Part I. Financial Information Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 3 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 28
Other Information
Part II. Other Information Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A.
Risk Factors
Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30 SIGNATURE PAGE 31 2 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements CYCLACEL PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS (In $000s, except share, per share, and liquidation preference amounts) (Unaudited) March 31, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 2,798 $ 3,378 Prepaid expenses and other current assets 2,037 4,066 Total current assets 4,835 7,444 Property and equipment, net 7 9 Right-of-use lease asset 79 93 Non-current deposits 1,244 1,259 Total assets $ 6,165 $ 8,805 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,200 $ 3,543 Accrued and other current liabilities 3,150 4,618 Total current liabilities 8,350 8,161 Lease liability 21 37 Total liabilities 8,371 8,198 Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; 6 % Convertible Exchangeable preferred stock; 335,273 shares issued and outstanding at March 31, 2024 and December 31, 2023. Aggregate preference in liquidation of $ 4,056,803 as of March 31, 2024 and $ 4,006,512 as of December 31, 2023 — — Series A convertible preferred stock, $ 0.001 par value; 264 shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Series B convertible preferred stock, $ 0.001 par value; 0 shares issued and outstanding at March 31, 2024 and 119,000 shares issued and outstanding at December 31, 2023 — — Common stock, $ 0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 1,318,259 shares issued and outstanding at March 31, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023 1 1 Additional paid-in capital 429,919 429,796 Accumulated other comprehensive loss ( 898 ) ( 908 ) Accumulated deficit ( 431,228 ) ( 428,282 ) Total stockholders' equity ( 2,206 ) 607 Total liabilities and stockholders' equity $ 6,165 $ 8,805 The ac